Pfizer Says Its Eczema Drug Bests Regeneron Rival in Late-Stage Trial
Pfizer said that its atopic dermatitis treatment abrocitinib demonstrated efficacy in a late-stage clinical trial that compared the treatment with Sanofi’s and Regeneron’s Dupixent (dupilumab).
The clinical study showed that a 200mg dose of abrocitinib was statistically superior compared to 300 mg of Dupixent (dupilumab) “in each evaluated efficacy measure,” Pfizer said.
The phase 3 trial, dubbed JADE DARE, was a 26-week, multicenter trial in 728 adult participants on background topical therapy for moderate-to-severe atopic dermatitis.
The trial’s primary efficacy endpoints were the proportion of patients achieving at least a 4-point improvement in the severity of Peak Pruritus Numerical Rating Scale from baseline at week two, and the proportion of patients achieving a 90 percent or greater Eczema Area and Severity Index improvement from baseline at week four.